5-{2-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-1-benzofuran-5-yl}-3-cyclopropyl-1,2,4-oxadiazole | 1254169-07-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-{2-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-1-benzofuran-5-yl}-3-cyclopropyl-1,2,4-oxadiazole
• 英文别名: 5-[2-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-5-yl]-1-benzofuran-5-yl]-3-cyclopropyl-1,2,4-oxadiazole
• CAS: 1254169-07-7
• 化学式: C₂₂H₁₄ClFN₄O₂
• 分子量: 420.83
• InChiKey: IHOUSVBIUIZWFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS D'ACIDE TÉTRAHYDROCYCLOPENTA[B]INDOL-3-YLCARBOXYLIQUE UTILES DANS LE TRAITEMENT DE TROUBLES AUTO-IMMUNS ET INFLAMMATOIRES
  申请人：ARENA PHARM INC

  公开号：WO2009078983A1

  公开（公告）日：2009-06-25

  The present invention relates to certain (1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl carboxylic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

  本发明涉及公式（Ia）中的某些（1,2,4-噁二唑-3-基）-1,2,3,4-四氢环-五氢-苯并[b]吲哚-3-基羧酸衍生物及其药学上可接受的盐，该衍生物具有有用的药理特性，例如作为S1P1受体的激动剂。本发明还提供了含有所述化合物的药物组合物，以及使用所述化合物和组合物治疗S1P1相关疾病的方法，例如银屑病、类风湿性关节炎、克罗恩病、移植排斥反应、多发性硬化症、系统性红斑狼疮、溃疡性结肠炎、I型糖尿病、痤疮、微生物感染或疾病以及病毒感染或疾病。
• TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2222668A1

  公开（公告）日：2010-09-01
• [EN] COMPOUNDS AND COMPOSITIONS AS MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS COMME INHIBITEURS DE LA PROSTAGLANDINE E SYNTHASE-1 MICROSOMALE
  申请人：IRM LLC

  公开号：WO2010127152A2

  公开（公告）日：2010-11-04

  Provided herein are compounds, and pharmaceutical compositions comprising such compounds, wherein the compounds are inhibitors of mPGES-1 activity. Also provided herein are methods of using such compounds and composition to treat or prevent diseases or disorders associated with the activity of mPGES-1.